Audentes Therapeutics, Inc. (BOLD) Major Shareholder Orbimed Advisors Llc Sells 5,000 Shares
Audentes Therapeutics, Inc. (NASDAQ:BOLD) major shareholder Orbimed Advisors Llc sold 5,000 shares of the firm’s stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $22.35, for a total value of $111,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Audentes Therapeutics, Inc. (BOLD) opened at 24.35 on Tuesday. The company has a 50-day moving average of $20.22 and a 200 day moving average of $17.37. The company’s market cap is $676.54 million. Audentes Therapeutics, Inc. has a 12 month low of $13.13 and a 12 month high of $24.50.
Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by $0.10. On average, equities analysts forecast that Audentes Therapeutics, Inc. will post ($3.53) earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN increased its position in shares of Audentes Therapeutics by 278.5% during the first quarter. Wells Fargo & Company MN now owns 7,747 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 5,700 shares during the period. Nationwide Fund Advisors increased its position in shares of Audentes Therapeutics by 288.9% during the second quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after buying an additional 6,384 shares during the period. Citadel Advisors LLC purchased a new position in shares of Audentes Therapeutics during the first quarter valued at about $184,000. State of Wisconsin Investment Board purchased a new position in shares of Audentes Therapeutics during the second quarter valued at about $210,000. Finally, Rhumbline Advisers purchased a new position in shares of Audentes Therapeutics during the second quarter valued at about $252,000. Institutional investors own 77.01% of the company’s stock.
BOLD has been the subject of several research reports. Zacks Investment Research upgraded Audentes Therapeutics from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a research note on Monday, July 17th. Wedbush restated an “ourperform” rating and issued a $20.00 target price on shares of Audentes Therapeutics in a research note on Monday, May 15th. ValuEngine upgraded Audentes Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, July 20th. Finally, Evercore ISI initiated coverage on Audentes Therapeutics in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $22.40.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Stock Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related stocks with our FREE daily email newsletter.